Efficacy of n-3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: Rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice

Trials

Volumn 11, Issue , 2010, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID; PLACEBO;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HEART INFARCTION; HOSPITALIZATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 77955148343     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-11-68     Document Type: Article

References (40)

1. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997, 18:1231-1248.
2. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999, 353:1547-1557. 10.1016/S0140-6736(99)04021-0, 10334252.
3. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757. 10.1016/S0140-6736(06)68770-9, 16731270.
4. Leal J, Leungo-Fernandez R, Gray A, Peterson S, Rayner M. Economic burden of cardiovascular disease in the enlarged European Union. Eur Heart J 2006, 27:1610-1619. 10.1093/eurheartj/ehi733, 16495286.
5. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003, 24:1601-1610. 10.1016/S0195-668X(03)00347-6, 12964575.
6. Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ Clinical research ed 1998, 316:1430-1434. 28543, 9572757.
7. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, . for the EUROASPIRE Study Group Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II and III surveys in eight European countries. Lancet 2009, 373:929-940. 10.1016/S0140-6736(09)60330-5, 19286092, for the EUROASPIRE Study Group.
8. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Inter Med 2001, 161:1621-1628.
9. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Family Practice 2002, 19:596-604. 10.1093/fampra/19.6.596, 12429661.
10. Roccatagliata D, Avanzini F, Monesi L, Caimi V, Lauri D, Longoni P, Marchioli R, Tombesi M, Tognoni G, Roncaglioni MC. Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level. Vascular Health and Risk Management 2006, 2:507-514. questa nostra referenza potremmo lasciarla qui, 10.2147/vhrm.2006.2.4.507, 1994019, 17323606.
11. Monesi L, Avanzini F, Barlera S, Caimi V, Lauri D, Longoni P, Roccatagliata D, Tombesi M, Tognoni G, Roncaglioni MC. Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?. Eur J Clin Pharmacol 2005, 61:595-601. questa nostra referenza potremmo lasciarla qui, 10.1007/s00228-005-0948-z, 16021439.
12. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW, . REACH Registry Investigators International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006, 295:180-189. 10.1001/jama.295.2.180, 16403930, REACH Registry Investigators.
13. Thomas P. The research needs of primary care. Trials must be relevant to patients. BMJ 2000, 321:2-3. 10.1136/bmj.321.7252.2, 1127682, 10875808.
14. De Maeseneer JM, van Driel ML, Green LA, van Weel C. The need for research in primary care. Lancet 2003, 362:1314-1319. 10.1016/S0140-6736(03)14576-X, 14575979.
15. Is primary-care research a lost cause?. Lancet 2003, 361:977. 10.1016/S0140-6736(03)12837-1, 12660048.
16. Collaborative Group of the Primary Prevention Project (PPP) Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001, 357:89-95. 10.1016/S0140-6736(00)03539-X, 11197445, Collaborative Group of the Primary Prevention Project (PPP).
17. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447-455. 10.1016/S0140-6736(99)07072-5, 10465168, Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.
18. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002, 105:1897-1903. 10.1161/01.CIR.0000014682.14181.F2, 11997274.
19. Roncaglioni MC, Avanzini F, Roccatagliata D, Monesi L, Tamayo-Benitez D, Tombesi M, Caimi V, Longoni P, Lauri D, Barlera S, Tognoni G. How general practitioners perceive and grade the cardiovascular risk of their patients. Eur J Cardiovasc Prev Rehabil 2004, 11:233-238. 10.1097/01.hjr.0000129737.84851.99, 15179106.
20. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. New Engl J Med 1985, 312:1205-1209.
21. Fish consumption and mortality from coronary heart disease. New Engl J Med 1985, 313:820-824.
22. Dolecek TA, Granditis G. Dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial (MRFIT). World Review of Nutrition and Dietetics 1991, 66:205-216.
23. Daviglus ML, Stamler J, Orencia AJ, Dyer AR, Liu K, Greenland P, Walsh MK, Morris D, Shekelle RB. Fish consumption and the 30-year risk of fatal myocardial infarction. New Engl J Med 1997, 336:1046-1053. 10.1056/NEJM199704103361502, 9091800.
24. Hu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, Hunter D, Manson JE. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. Jama 2002, 287:1815-1821. 10.1001/jama.287.14.1815, 11939867.
25. Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, Bovbjerg V, Arbogast P, Smith H, Kushi LH, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. Jama 1995, 274:1363-1367. 10.1001/jama.274.17.1363, 7563561.
26. Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ, Willett WC, Ruskin JN, Manson JE. Fish consumption and risk of sudden cardiac death. Jama 1998, 279:23-28. 10.1001/jama.279.1.23, 9424039.
27. Mozaffarian D, Lemaitre RN, Kuller LH, Burke GL, Tracy RP, Siscovick DS. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular Health Study. Circulation 2003, 107:1372-1377. 10.1161/01.CIR.0000055315.79177.16, 12642356.
28. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. New Engl J Med 2002, 346:1113-1118. 10.1056/NEJMoa012918, 11948270.
29. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989, 2:757-761. 10.1016/S0140-6736(89)90828-3, 2571009.
30. Kang JX, Leaf A. Effects of long-chain polyunsaturated fatty acids on the contraction of neonatal rat cardiac myocytes. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:9886-9890. 10.1073/pnas.91.21.9886, 44922, 7937911.
31. McLennan PL, Bridle TM, Abeywardena MY, Charnock JS. Dietary lipid modulation of ventricular fibrillation threshold in the marmoset monkey. Am Heart J 1992, 123:1555-1561. 10.1016/0002-8703(92)90809-A, 1595535.
32. Christensen JH, Gustenhoff P, Ejlerseu E, Jessen T, Korup E, Rasmussen K, Dyerberg J, Schmidt EB. Fatty Acids And Ventricular Extrasystoles In Patients With Ventricular Tachyarrhythmias. Nutrition Research 1995, 15:1-8.
33. Leaf A. The electrophysiological basis for the antiarrhythmic actions of polyunsaturated fatty acids. Eur Heart J 2001, 3(Suppl):D98-D105.
34. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757. 10.1161/01.CIR.0000038493.65177.94, 12438303.
35. Avanzini F, Alli C, Bettelli G, Colombo F, Conforti L, Pirone F, Spagnoli A, Taioli E, Tognoni G, Villella M, et al. Feasibility of a large prospective study in general practice: an Italian experience. Gruppo di Studio sulla Pressione Arteriosa nell'Anziano. BMJ Clinical research ed 1987, 294:157-160.
36. Cox DR. Regression Models and Life Tables (with Discussion). Journal of the Royal Statistical Society 1972, 34:187-220.
37. Kalbfeisch JD, Prentice RL. The statistical analysis of failure time data 1980, New York: John Wiley and Sons Inc.
38. Geller NL, Pocock SJ. Interim Analysis in Randomized Clinical Trials: Ramifications and Guidelines for Practitioners. Biometrics 1987, 43:213-223. 10.2307/2531962, 3567306.
39. GISSI-HF Investigators Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230. 10.1016/S0140-6736(08)61239-8, 18757090, GISSI-HF Investigators.
40. Yamagishi K, Iso H, Date C, Fukui M, Wakai K, Kikuchi S, Inaba Y, Tanabe N, Tamakoshi A. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. JACC 2008, 52:988-996.